Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report

By sjmartinez • February 28, 2025

Fitzsimmons KC, Fajardo MA, Noor Z. Exceptional response to TROP2 inhibition with sacituzumab govitecan in a patient with small cell carcinoma of the breast: a case report. Ther Adv Med Oncol. 2025 Feb 26;17:17588359251322003. doi: 10.1177/17588359251322003. PMID: 40017901; PMCID: PMC11866389.

Tags: Hematology/Oncology, neuroendocrine tumor breast, Publications, sacituzumab govitecan-hziy, small cell carcinoma of the breast, TROP2 inhibition

CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours

Hecht JR, Michot JM, Bajor D, Patnaik A, Chung KY, Wang J, Falchook G, Cleary JM, Kim R, Krishnamurthy A, Marathe O, Youssoufian H, Ellis[...]

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu[...]

Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer

Podany EL, Foffano L, Gerratana L, Medford AJ, Clifton K, Tapiavala S, Velimirovic M, Lipsyc-Sharf M, Reduzzi C, Bubie A, Putur A, Ademuyiwa FO, Puglisi[...]